In trading on Thursday, shares of Perspective Therapeutics Inc (Symbol: CATX) touched a new 52-week high of $1.87/share. That’s a 835.00% rise, or $1.67 per share from the 52-week low of $0.20 set back on 09/15/2023. That means at today’s intraday high, any investor who purchased CATX stock any time over the past 52 weeks has an unrealized gain, including company insiders.
Over the past six months, insiders have been scooping up shares, and those bets are now paying off handsomely. As summarized by the table below, CATX has seen 3 different instances of insiders buying over the trailing six month period.
| Purchased | Insider | Title | Shares | Price/Share | Value |
|---|---|---|---|---|---|
| 12/18/2023 | Jonathan Robert Hunt | Chief Financial Officer | 125,000 | $0.26 | $32,337.50 |
| 12/19/2023 | Robert F. Williamson III | Director | 23,680 | $0.29 | $6,977.60 |
| 12/19/2023 | Markus Puhlmann | Chief Medical Officer | 595,425 | $0.32 | $188,737.33 |
| 12/21/2023 | Robert F. Williamson III | Director | 3,663 | $0.33 | $1,202.56 |
| 01/24/2024 | Markus Puhlmann | Chief Medical Officer | 280,000 | $0.50 | $139,888.00 |
| 01/25/2024 | Robert F. Williamson III | Director | 51,996 | $0.49 | $25,478.04 |
| 01/30/2024 | Robert F. Williamson III | Director | 127,206 | $0.71 | $90,710.05 |
| 03/06/2024 | Lantheus Alpha Therapy, LLC | 60,431,039 | $0.95 | $57,409,487.05 |
The chart below shows where CATX has traded over the past year, with the 50-day and 200-day moving averages included.
In afternoon trading on Thursday, CATX shares are changing hands at $1.79/share, slightly below the new 52-week high.
Ten Bargains You Can Buy Cheaper Than The Insiders Did »
Also see:
Top Ten Hedge Funds Holding NRE
Institutional Holders of JEWL
Funds Holding NINE
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
